Get the Stockscreener App
0.601
10.30%
-0.069
After Hours:
.63
0.029
+4.83%
Scinai Immunotherapeutics Ltd Adr stock is traded at $0.601, with a volume of 34,772.
It is down -10.30% in the last 24 hours and down -30.92% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
See More
Previous Close:
$0.67
Open:
$0.677
24h Volume:
34,772
Relative Volume:
0.80
Market Cap:
$2.08M
Revenue:
$1.26M
Net Income/Loss:
$-8.55M
P/E Ratio:
-0.049
EPS:
-12.2724
Net Cash Flow:
$-6.38M
1W Performance:
-14.75%
1M Performance:
-30.92%
6M Performance:
-54.47%
1Y Performance:
-82.35%
1-Day Range:
$0.55
$0.704
1-Week Range:
$0.55
$0.74
52-Week Range:
$0.55
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.601 | 2.32M | 1.26M | -8.55M | -6.38M | -12.27 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Sahm
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Benzinga
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Barchart.com
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - Barchart
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing By Investing.com - Investing.com South Africa
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Finviz
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Announces Annual Financial Results for 2024 - Finviz
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Expands CDMO Operations with New U.S. Subsidiary - The Globe and Mail
CERo Therapeutics (CERO) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Scinai Immunotherapeutics (SCNI) Stock Forecast and Price Target 2025 - MarketBeat
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics (SCNI) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Scinai Immunotherapeutics Ltd. Sponsored ADR Cash Flow – NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Institutional Ownership 2025 - MarketBeat
SCNI Stock Price and Chart — NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics (SCNI) Earnings Date and Reports 2026 - MarketBeat
Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis - MarketBeat
Scinai Immunotherapeutics Ltd Share Price ADR Each Representing 400 Ord Shares SPON - Hargreaves Lansdown
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):